Results 191 to 200 of about 5,054 (206)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data

Clinical, Cosmetic and Investigational Dermatology, 2023
Angelo Ruggiero, Matteo Megna, Luca Potestio   +2 more
exaly  

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Journal of the American Academy of Dermatology, 2017
Kristian Reich, Peter Foley, Michael Song   +2 more
exaly  

Apremilast/guselkumab

Reactions Weekly, 2022
openaire   +1 more source

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study

Journal of Dermatology, 2018
Hiroshi Kubo, Mamitaro Ohtsuki, Hitomi Morishima   +2 more
exaly  

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

Journal of Clinical Medicine, 2020
Luca Bianchi, Marina Talamonti, Marco Galluzzo   +2 more
exaly  

Brodalumab/guselkumab

Reactions Weekly, 2021
openaire   +1 more source

Guselkumab/secukinumab/ustekinumab

Reactions Weekly, 2022
openaire   +1 more source

<p>Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis</p>

Drug Design, Development and Therapy, 2019
Tina Bhutani, Mary Patricia Smith, Karen Ly   +2 more
exaly  

Belimumab/guselkumab

Reactions Weekly, 2020
openaire   +1 more source

Guselkumab/methotrexate/tozinameran

Reactions Weekly, 2022
openaire   +1 more source